Shares of Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) were up 1.7% during trading on Thursday . The company traded as high as $54.14 and last traded at $53.74. Approximately 366,596 shares were traded during mid-day trading, an increase of 94% from the average daily volume of 189,291 shares. The stock had previously closed at $52.83.
Gemini Therapeutics Price Performance
The firm’s 50 day moving average is $55.40 and its 200 day moving average is $55.98. The company has a market cap of $2.26 billion, a PE ratio of -52.24 and a beta of -0.12.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Further Reading
- Five stocks we like better than Gemini Therapeutics
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- Top Biotech Stocks: Exploring Innovation Opportunities
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
